Illinois Municipal Retirement Fund Buys 25,298 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Illinois Municipal Retirement Fund raised its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 67.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 62,665 shares of the biopharmaceutical company’s stock after acquiring an additional 25,298 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Alnylam Pharmaceuticals were worth $14,746,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in ALNY. Jennison Associates LLC acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $61,160,000. Strategic Financial Concepts LLC acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $41,529,000. Eventide Asset Management LLC lifted its position in Alnylam Pharmaceuticals by 157.9% during the 3rd quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company’s stock worth $61,698,000 after buying an additional 137,333 shares in the last quarter. Los Angeles Capital Management LLC increased its holdings in Alnylam Pharmaceuticals by 11,433.4% during the third quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after buying an additional 135,829 shares during the last quarter. Finally, Telemark Asset Management LLC bought a new position in Alnylam Pharmaceuticals during the third quarter worth $27,503,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $248.94 on Tuesday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The stock has a fifty day simple moving average of $254.24 and a two-hundred day simple moving average of $262.90. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insiders Place Their Bets

In other news, CMO Pushkal Garg sold 52,592 shares of the firm’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the sale, the chief marketing officer now owns 11,989 shares in the company, valued at $3,416,865. This trade represents a 81.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Phillip A. Sharp sold 11,250 shares of the firm’s stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 72,986 shares of company stock worth $20,397,849. Company insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

ALNY has been the topic of several research reports. Morgan Stanley lifted their price target on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. Needham & Company LLC restated a “buy” rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, February 14th. Wolfe Research lowered Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research report on Tuesday, November 12th. Barclays boosted their price target on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research report on Friday, November 1st. Finally, HC Wainwright increased their price objective on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a research report on Monday. One research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $303.83.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.